IDT Biologika

Photo
01.07.2024 • News

SK Bioscience Acquires Majority Stake in IDT Biologika

South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.

Photo
04.03.2022 • News

IDT Biologika and Exothera Join on Vaccine Scale-up

IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, is collaborating with Belgian CDMO Exothera on developing a large-scale manufacturing process for viral vector-based vaccines. The two firms are currently conducting a feasibility study focused on the Modified Vaccinia Ankara (MVA) virus as a first project to come out of IDT’s broad range of vector technologies.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.